Media Pack
News

Current Edition

Volume 16 Issue 3
 
 
Regional News

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war

Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are among...
17 March 2022 Regional News AbbVie | Eli Lilly
Continue Reading →
Regional News

FDA chides Eli Lilly for second misleading ad in 2 months, this time for diabetes blockbuster Trulicity

After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion. The ...
26 January 2022 Regional News diabetes | drugmaker
Continue Reading →
Regional News

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and pharma reps. As with...
13 December 2021 Regional News Amgen | Bristol Myers Squibb
Continue Reading →
Regional News

Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted "weaknesses" in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The "outra...
13 December 2021 Regional News diabetes | drug costs
Continue Reading →
Regional News

AbbVie’s Rinvoq, Pfizer’s Xeljanz and Lilly’s Olumiant slapped with new FDA warnings amid JAK safety crackdown

The second regulatory shoe has finally dropped for AbbVie, Pfizer and Eli Lilly amid the safety review of JAK inhibitors for inflammatory diseases. But confirmed labe...
8 December 2021 Regional News AbbVie | atopic dermatitis
Continue Reading →
Regional News

GlaxoSmithKline and Vir’s sotrovimab stands up to omicron despite other COVID antibodies falling short

Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnolog...
8 December 2021 Regional News antibodies | Celltrion
Continue Reading →
Regional News

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze

On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi...
1 December 2021 Regional News china | drug prices
Continue Reading →
Regional News

Eli Lilly and Boehringer Ingelheim’s Jardiance stays on its heart failure winning streak⁠—this time in acute patients

Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data th...
17 November 2021 Regional News acute heart failure | Boehringer Ingelheim
Continue Reading →
Regional News

J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson's Invokana is vying for a piece of the lucrative heart failure market. J&am...
17 November 2021 Regional News AstraZeneca | Eli Lilly
Continue Reading →
Regional News

Lilly and Boehringer’s Jardiance shows benefits for those with ‘intimately linked’ heart failure and kidney disease

Heart failure and chronic kidney disease often go hand in hand. And when they do, the risk of death and hospitalization increase. A new analysis from Eli Lilly and B...
10 November 2021 Regional News Boehringer Ingelheim | chronic kidney disease
Continue Reading →
 
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte